Twist Bioscience Completes $37M Series C Round | GenomeWeb

NEW YORK (GenomeWeb) – Synthetic DNA firm Twist Bioscience announced today the completion of a $37 million Series C financing round. 

The round was led by Illumina. New investors Fidelity Management and Research and Foresite Capital Mangement also participated in the round, as did all existing investors including Nick and Joby Pritzker through their family's firm Tao Invest; Arch Invest Venture Partners; Paladin Capital Group; Yuri Milner; and other corporate and venture investors. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.